We came across a bullish thesis on AbbVie Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.'s share was trading at $233.91 as of October 3rd. ABBV’s trailing and forward P/E were 112.65 and 16.84 respectively according to Yahoo Finance.
[caption id="attachment_364539" align="aligncenter" width="750"]AbbVie is advancing its oncology portfolio through two targeted chemo antibody-drug conjugates (ADCs), Elahere and Emrelis, which focus on cancers...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.